Shares of vaccine maker Moderna (MRNA.O) up 3.1% at $45.33 premarket Co says the U.S. FDA accepted its application to review mRNA-1010, a vaccine targeting seasonal influenza using messenger RNA technology The FDA had initially refused to review the vaccine, citing flaws in the trial design MRNA says it has sought full approval for the vaccine for ages 50 to 64 years and a faster, conditional approval for those above 65 years of age with “a post-marketing requirement to conduct an additional study in older adults” Also adds that the vaccine, if approved, could be made available as early as the 2026⁄27 flu season  mRNA-1010 is also being reviewed in Europe, Canada and Australia Shares fell ~29% in 2025

MRNA

Reuters

First Trust NYSE Arca Biotech Index Fd

iShares US Pharma

Moderna

iShares Global Healthcare

VG Health

SPDR S&P Biotech

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

Health Care Select Sector SPDR

BUZZ-Moderna rises after US FDA agrees to review its flu vaccine